Interview 7 Nov 2022 AI could tackle pharmaceutical manufacturing bottlenecks Artificial intelligence (AI) is making waves in the world of drug discovery. Rajiv Anand, founder and CEO of the firm Quartic.ai, explains how the tool could also make pharmaceutical manufacturing more efficient. The use of AI in drug discovery is attracting big investor interest; around $1.4 billion so far this year has gone to startups […] November 7, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 7 Nov 2022 Sensorion granted rare pediatric disease designation by FDA for lead therapy gene Sensorion has announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation to its lead therapy gene candidate, OTOF-GT. The gene therapy is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion’s OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one […] November 7, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 TMRW Life Sciences FDA-approved tech will help more people start families Fertility technology company, TMRW Life Sciences Inc., has received FDA clearance for its latest technology that will help more people build families. The CryoRobot Select marks the latest milestone in the company’s expansion of its technology-enabled portfolio. USA-based TMRW says advances like theirs in assisted reproductive technology are helping people start families when they otherwise […] November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study Scancell Holdings plc, a developer of immunotherapies, today (November 7) announced it has in-licensed the SNAPvax technology from Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines. The agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a phase 1 clinical study […] November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Proteins identified by FunSel and developed by Forcefield can preserve heart function Forcefield Therapeutics, has presented positive preclinical data on three proteins identified by it FunSel platform that have the potential to preserve heart function following a heart attack. The company that works with therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction infarction. The paper, Novel Recombinant Cardioprotective Factors Against Myocardial […] November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Ascentage Pharma gives positive news on chronic hepatitis B drug Ascentage Pharma has released results from a phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB). The results were presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world’s first clinical study reporting […] November 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 First patient dose completed for bladder cancer diagnostic drug Asieris Pharmaceuticals says it has completed the first patient dose in its phase III bridging trial for Hexvix, a drug used for the diagnosis of bladder cancer. Asieris Pharmaceuticals is a global biopharmaceutical company specializing in the discovery and development of drugs for the treatment of genitourinary tumors and other major diseases. The study is a […] November 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo. The results were announced today during the American Society of […] November 4, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 4 Nov 2022 Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November 4). The European Commission has approved Beyfortus which is so far the first and only broadly protective option against the virus. Thomas Triomphe, executive vice president, […] November 4, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 4 Nov 2022 Optibrium and Lhasa Limited study published on predictive modelling for enzymes A peer reviewed study published in the Journal of Medicinal Chemistry has been published by Optibrium and Lhasa Limited that shows advance predictive modelling for drug-metabolizing enzymes. The companies are two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development. In the paper, ‘Predicting Regioselectivity of AO, CYP, […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Centogene launches rare and neurodegenerative disease Biodata Network German company, Centogene N.V., today (November 4) announced its launch of Biodata Network, a portfolio of data-driven partnering solutions including licenses and insight report for biopharma and research institutions. The company, which works to find data-driven answers in rare and neurodegenerative diseases, wants to offer increased access to its insights. To do this, it has […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Creative Medical Technology Holdings announces FDA clearance of diabetes drug Creative Medical Technology Holdings yesterday (November 3) announced its investigational new drug (IND) application has been cleared by the U.S. Food and Drug Administration (FDA). This will enable the company to start initiating a clinical trial for type 1 diabetes using AlloStem. The primary objective of the study is to evaluate Allostem in patients with […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email